Safety and feasibility of fasting in combination with platinum-based chemotherapy

• Published in: BMC cancer Vol. 16; no. 1; p. 360
• Main Authors: Dorff, Tanya B., Groshen, Susan, Garcia, Agustin, Shah, Manali, Tsao-Wei, Denice, Pham, Huyen, Cheng, Chia-Wei, Brandhorst, Sebastian, Cohen, Pinchas, Wei, Min, Longo, Valter, Quinn, David I.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.06.2016; BioMed Central
• Subjects: Adult; Aged; Biomarkers; Biomarkers - blood; Biomarkers - metabolism; Cancer; Cancer patients; Cancer therapies; Chemotherapy; Clinical trials; Consent; Data analysis; Fasting; Fasting - blood; Feasibility Studies; Female; Food; Gene expression; Health aspects; Humans; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factors; Male; Middle Aged; Neoplasms - blood; Neoplasms - drug therapy; Oxidative Stress; Platinum - adverse effects; Platinum - therapeutic use; Safety and security measures; Studies; Treatment Outcome; Tumors; Oxidative stress; Chemotherapy; Fasting; Insulin-like growth factor; Neutropenia

Short-term starvation prior to chemotherapy administration protects mice against toxicity. We undertook dose-escalation of fasting prior to platinum-based chemotherapy to determine safety and feasibility in cancer patients. 3 cohorts fasted before chemotherapy for 24, 48 and 72 h (divided as 48 pre-...